Suitability-for-use considerations for prefilled syringes

Pharmaceutical Technology

Volumn 32, Issue SUPPL., 2008, Pages

  Jenke, Dennis ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTAINERS; DRUG PRODUCTS; DRUG PRODUCTS PLANTS; LAWS AND LEGISLATION;

PHARMACEUTICAL INDUSTRY;

SYRINGES;

SILICONE OIL; TUNGSTEN;

DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG PACKAGING; LEACHING; MATERIAL COATING; PREFILLED SYRINGE; SHORT SURVEY;

EID: 42349086628     PISSN: 15432521     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (21)

1. D.E. Overcashier, E.K. Chan, and C.C. Hsu, "Technical Considerations in the Development of Prefilled Syringes for Protein Products," Am. Pharm. Rev. 9 (7), 77-83 (2006).
2. M.N. Eakins, "The Design and Construction of Prefilled Syringes", Am. Pharm. Rev. 10 (6), 47-51 (2007).
3. B. Harrison and M. Rios, "Big Shot: Developments in Prefilled Syringes," Pharm. Technol. 30 (5), 42-48 (2007).
4. Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics (US Department of Health and Human Services, Food and Drug Administration, Rockville, MD, May, 1999).
5. Guideline on Plastic Immediate Packaging Materials (European Medicines Agency, CPMP/QWWP/4359/03, EMEA/CVMP/205/04, May, 2005).
6. D. Jenke, "Evaluation of the Chemical Compatibility of Plastic Contact Materials and Pharmaceutical Products; Safety Consideration related to Extractables and Leachables," J. Pharm. Sci. 96 (10), 2566-2581 (2007).
7. M.J. Akers, S.L. Nail, and W. Saffell-Chamber, "Top Ten Hot Topics in Parenteral Science and Technology," PDA J. Pharm. Sci. Technol. 61 (5), 337-361 (2007).
8. K. Nicholas, "Extractables and Leachables Determination: A Systematic Approach to Select and Qualify a Container Closure System For a Pharmaceutical Product," Am. Pharm. Rev. 9 (3), 21-27 (2006).
9. I. Markovic. "Evaluation of Safety and Quality Impact of Extractable and Leachable Substances in Therapeutic Biologic Protein Products: A Risk-Based Perspective," Expert Opin. Drug. Saf. 6 (5), 487-491 (2007).
10. D.J. Ball, D.L. Norwood, and L. Nagao, "Utility and Application of Analytical and Safety Thresholds for the Evaluation of Extractables and Leachables in Drug Products," Am. Pharm. Rev. 10 (5), 16-21 (2007).
11. H. Lee et al., "Tungsten Leaching from Prefilled Syringes and Impact on Protein Aggregation," poster presented at the PDA Extractables/ Leachables Forum, Confronting Extractables and Leachables Issues in an Evolving Industry, Bethesda, Maryland, November 6-8, 2007.
12. R.E. Osterberg, "Potential Toxicity of Extractables and Leachables in Drug Products," Am. Pharm. Rev. 8 (2), 64-67 (2005).
13. A.S. Rosenberg and A.S. Worobec, "A Risk-Based Approach to Immunogenicity Concerns of Therapeutic Protein Products, Part 2: Considering Host-Specific and Product-Specific Factors Impacting Immunogenicity," BioPharm Int. 17 (12), 34-40 (2004).
14. I. Markovic, "Challenges Associated with Extractable and/or Leachable Substances in Therapeutic Biologic Protein Products," Am. Pharm. Rev. 9 (6), 20-27 (2006).
15. Z.Q. Wen et al., "Investigation of Contaminants in Protein Pharmaceuticals in Prefilled Syringes by Multiple Microspectroscopies," Am. Pharm. Rev. 10 (5), 101-107 (2007).
16. B. Sharma, "Immunogenicity of Therapeutic Proteins Part 2. Impact of Container Closures." Biotech. Adv. 25 (3), 318-324 (2007).
17. L.S. Jones, A. Kaufmann, and C.R. Middaugh, "Silicone Oil Induced Aggregation of Proteins," J. Pharm. Sci. 94 (4), 918-927 (2004).
18. D.E. Overcashier, E.K. Chan, and C.C. Hua, "Technical Considerations in the Development of Prefilled Syringes for Protein Products," Am. Pharm. Rev. 9 (7), 77-83 (2006).
19. B. Sharma et al., "Technical Investigations into the Cause of the Increased Incidence of Antibody-Mediated Pure Red Cell Aplasia Associated with Eprex," Eur. J. Hosp. Pharm. 5, 86-91 (2004).
20. K. Boven et al., "Epoetin-Associated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease: Solving the Mystery," Nephr. Dialy. Trans. 20 (suppl. 3), ii30-ii40 (2005)
21. J. Pang et al., "Recognition and Identification of Leachables in EPREX Prefilled Syringes: An Unexpected Occurrence at a Formulation-Component Interface," PDA J. Pharm. Sci. Technol. 61 (6), 423-432 (2007).